Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in chinese patients with chronic hepatitis B during lamivudine treatment

Hepatobiliary and Pancreatic Diseases International

Volumn 11, Issue 2, 2012, Pages 172-176

  Wu, Feng ^a   Wu, Min Jin ^a   Zhuge, Xiao Lin ^a   Zhu, Shao Ming ^a   Zhu, Biao ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; HBV genotype; Lamivudine therapy; YMDD mutations

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHINESE; CHRONIC HEPATITIS; CORRELATION ANALYSIS; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; YMDD GENE;

EID: 84859875335     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(12)60144-1     Document Type: Article

References (31)

1. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebocontrolled trial. Hepatology 1997;25:241-244.
2. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
3. Furusyo N, Takeoka H, Toyoda K, Murata M, Tanabe Y, Kajiwara E, et al. Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study. World J Gastroenterol 2006;12:561-567.
4. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33: 1527-1532.
5. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791.
6. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
7. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 2002;37:366-369.
8. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
9. Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002;299:88-99.
10. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 2005;12:398-404.
11. Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol 2005;43:72-77.
12. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during longterm treatment. J Hepatol 2003;38:315-321.
13. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003;46:182-189.
14. Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004;39:42-50.
15. Min XC, Miao XH, Zhao SM, Zhao KK, Yang DG. The spontaneous YMDD mutation rate in chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2009;17:887-890.
16. Zhao J, Guo Y, Yan Z, Liang P, Zhang J, Liu Y. The natural YMDD mutations of hepatitis B virus in Western China. Scand J Infect Dis 2012;44:44-47.
17. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999;80:97-112.
18. Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C. J Viral Hepat 2007;14:767-774.
19. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696.
20. Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, et al. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011;17:2945-2952.
21. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--largescale analysis using a new genotyping method. J Infect Dis 1997;175:1285-1293.
22. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67-74.
23. Bartholomeusz A, Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol 2004;14: 3-16.
24. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24-34.
25. Buti M, Cotrina M, Valdes A, Jardi R, Rodriguez-Frias F, Esteban R. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002;36:445-446.
26. Zöllner B, Petersen J, Schröter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001;357:934-935.
27. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
28. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-1153.
29. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088.
30. Kobayashi M, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Sezaki H, et al. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res 2010;40:125-134.
31. Tsubota A, Arase Y, Suzuki F, Kobayashi M, Matsuda M, Sato J, et al. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J Med Virol 2004;73:7-12.